Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-17T00:48:28.592Z Has data issue: false hasContentIssue false
  • English
  • Français

Advances in the Management of Fibromyalgia

Published online by Cambridge University Press:  07 November 2014

Lesley M. Arnold
Get access Rights & Permissions [Opens in a new window]

Extract

The presentation of fibromyalgia syndrome (FM) is heterogeneous. Hence, the goal of treatment is to develop an individualized approach that takes into account the severity of the patient's pain, the presence and severity of other symptoms and comorbidities or stressors, and the degree of functional impairment. This includes the identification and treatment of all pain sources that might be present in addition to FM, such as peripheral pain generators (eg, comorbid osteoarthritis or neuropathic pain) or visceral pain disorders (eg, comorbid irritable bowel syndrome). It is also important to address other symptoms or disorders that commonly occur in patients with FM, such as fatigue, sleep disturbances, and comorbid sleep disorders (eg, sleep apnea). Cognitive impairment, stiffness, mood disorders, and anxiety disorders are also commonly reported in patients with FM. Finally, the treatment should strive to improve the patient's function and global health status. In most cases, the management involves both pharmacologic and nonpharmacologic treatments (Slide 1).

Type
Expert Review Supplement
Information
CNS Spectrums , Volume 14 , Issue S8: Clinical Case Update in Fibromyalgia Management , October 2009 , pp. 12 - 16
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Arnold, LM. Biology and therapy of FM. New therapies in FM. Arthritis Res Ther. 2006;8(4):212.CrossRefGoogle Scholar
2.US Food and Drug Administration. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed March 27, 2009.Google Scholar
3.Basbaum, AI, Fields, HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann Rev Neurosci. 1984;7:309–338.CrossRefGoogle ScholarPubMed
4.Millan, MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474.CrossRefGoogle ScholarPubMed
5.Fishbain, D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32(5):305–316.CrossRefGoogle ScholarPubMed
6.Arnold, LM, Keck, PE Jr, Welge, JA. Antidepressant treatment of FM. A meta-analysis and review. Psychosomatics. 2000;41(2):104–13.CrossRefGoogle Scholar
7.Arnold, LM, Pritchett, YL, D'Souza, DN, Kajdasz, DK, Iyengar, S, Wernicke, JF. Duloxetine for the treatment of FM in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt). 2007;16(8):1145–1156.CrossRefGoogle Scholar
8.Clauw, DJ, Mease, P, Palmer, RH, Gendreau, RM, Wang, Y. Milnacipran for the treatment of FM in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988–2004.CrossRefGoogle ScholarPubMed
9.Zijlstra, TR, Barendregt, PJ, van de Laar, MAF. Venlafaxine in fibromyalgia: Results of a randomized, placebo-controlled, double-blind trial. Presented at the 66th Annual Meeting of the American College of Rheumatology, 2002. Available at: www.rheumatol-ogy.org, abstract 179).Google Scholar
10.Woolf, CJ; American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140(6):441–451.CrossRefGoogle ScholarPubMed
11.Fehrenbacher, JC, Taylor, CP, Vasko, MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105(1–2):133–141.CrossRefGoogle ScholarPubMed
12.Maneuf, YP, Hughes, J, McKnight, AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain. 2001;93(2):191–196.CrossRefGoogle Scholar
13.Arnold, LM et al. Abstract presented at the Annual European Congress of Rheumatology, EULAR 2007; June 13–16, 2007; Barcelona, Spain. Abstract #OP0036.Google Scholar
14.Arnold, LM, Russell, IJ, Diri, EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with FM. J Pain. 2008;9(9):792–805.CrossRefGoogle Scholar
15.Mease, PJ, Russell, IJ, Arnold, LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with FM. J Rheumatol 2008;35(3):502–514.Google Scholar
16.Arnold, LM, Goldenberg, DL, Stanford, SB, et al. Gabapentin in the treatment of fibromy-algia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336–1344.CrossRefGoogle Scholar
17.Rooks, DS, Gautam, S, Romeling, M, et al. Group exercise, education, and combination self-management in women with FM: a randomized trial. Arch Intern Med. 2007;167(20):2192–2200.CrossRefGoogle Scholar
18.Busch, AJ, Barber, KA, Overend, TJ, Peloso, PM, Schachter, CL. Exercise for treating FM syndrome. Cochrane Database Syst Rev. 2007;(4):CD003786.CrossRefGoogle Scholar
19.Williams, DA, Cary, MA, Groner, KH, et al. Improving physical functional status in patients with FM: a brief cognitive behavioral intervention. J Rheumatol. 2002;29(6):1280–1286.Google ScholarPubMed
20.Chu, LF, Clark, DJ, Angst, MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain. 2006;7(1):43–48.CrossRefGoogle ScholarPubMed
21.King, T, Gardell, LR, Wang, R, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain. 2005;116(3):276–288.CrossRefGoogle ScholarPubMed
22.Senay, EC, Adams, EH, Geller, A, et al. Physical dependence on Ultram ® (tramadol hydro-chloride): Both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003,69:233–241.CrossRefGoogle Scholar